Global state ‐ number of participants with relapse/exacerbations of psychosis (combined time points) · patients with schizophrenia
Summary of findings table ‐ Antipsychotic dose reduction may leads to higher global state ‐ number of participants with relapse/exacerbations of… compared with dose continuation (low certainty).
1 finding from 1 review
Leaving the study early ‐ for any reason ‐ overall acceptability (combined time points) · patients with schizophrenia
Summary of findings table ‐ Antipsychotic dose reduction probably leads to higher leaving the study early ‐ for any reason ‐ overall acceptability… compared with dose continuation (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with schizophrenia
Summary of findings table ‐ Antipsychotic dose reduction showed no clear difference in adverse effects ‐ number of participants with at least 1 adverse… compared with dose continuation (moderate certainty).
1 finding from 1 review
Global state: clinically relevant response: · non response in schizophrenia
Antipsychotic dose increase showed no clear difference in global state: clinically relevant response: compared with antipsychotic dose continuation (low certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · non response in schizophrenia
It is very uncertain whether antipsychotic dose increase changes leaving the study early: tolerability ‐ leaving early due to adverse… compared with antipsychotic dose continuation (very low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · non response in schizophrenia
Antipsychotic dose increase showed no clear difference in leaving the study early: acceptability ‐ leaving early due to any… compared with antipsychotic dose continuation (low certainty).
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · non response in schizophrenia
1 finding from 1 review
Risk for at least one adverse event per patient · non response in schizophrenia
It is very uncertain whether antipsychotic dose increase changes adverse effects ‐ at least one adverse effect compared with antipsychotic dose continuation (very low certainty).
1 finding from 1 review
Service use: time in hospital · non response in schizophrenia
1 finding from 1 review
Proportion of participants with at least 50% improvement in their quality of life ‐ not reported · non response in schizophrenia
1 finding from 1 review
Weight (kg) · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Weight: 2a. BMI ‐ Increase · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes weight: 2a. BMI ‐ Increase compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (very low certainty).
1 finding from 1 review
Physiological measures: 1c. Average fasting glucose change ‐ switching to aripiprazole and quetiapine · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Relapse · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in global state: Relapse compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (low certainty).
1 finding from 1 review
Adverse events: 1a. Serious adverse event ‐ switching to aripiprazole · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in adverse events: 1a. Serious adverse event ‐ switching to aripiprazole compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (low certainty).
1 finding from 1 review
Satisfaction with care: Loss to · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
It is very uncertain whether SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN changes satisfaction with care: Loss to compared with CONTINUATION ON PREVIOUS REGIMEN: 1b. NEW ATYPICAL from OLANZAPINE ‐… (very low certainty).
1 finding from 1 review
Weight: BMI not improved · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Physiological measure: Metabolic syndrome · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
1 finding from 1 review
Global state: Changing dose because of deterioration ‐ switching to haloperidol decanoate from fluphenazine decanoate · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in global state: Changing dose because of deterioration ‐ switching to… compared with CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from… (low certainty).
1 finding from 1 review
Mental state: Deteriorated ‐ switching to haloperidol decanoate from fluphenazine decanoate · patients with people with schizophrenia who have neuroleptic‐induced weight or metabolic problems
SWITCHING ‐ NEW ANTIPSYCHOTIC REGIMEN showed no clear difference in mental state: Deteriorated ‐ switching to haloperidol decanoate from… compared with CONTINUATION ON PREVIOUS REGIMEN: 1a. DIFFERENT DEPOT from… (low certainty).
1 finding from 1 review